The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of thrombus is listed in the mitraclip g4 system instructions for use (ifu) as a known possible complication associated with mitraclip procedures.Based on available information, a cause for the reported thrombus could not be determined.The reported required medication is the result of case-specific circumstances.There is no indication of a product issue with respect to manufacture, design, or labeling.
|
This is filed for thrombosis.It was reported that this was a mitraclip procedure to treat degenerative mitral regurgitation (mr) of grade 4+.The patient was administered 5000 units of heparin and the activated clotting time (act) was greater than 400.The guide wire was advanced into the anatomy and across the septum without issue.The steerable guide catheter (sgc) was advanced into the patient anatomy without issue; however, when the sgc reached the right atrium, a large clot was noted on the guide wire in the right atrium.The sgc was removed and additional heparin was administered.The sgc was re-prepped for re-insertion; however, it was noted that the clot remained.A full dose of angiomax was administered, but the clot remained.The decision was made to abort the procedure and monitor the patient condition.At the end of the procedure, the patient was in stable condition.The plan is to have the patient return to the operating room for transesophageal echocardiogram (tee).If the clot remains, additional intervention will be performed.No additional information was provided.
|